Clinical outcomes of patients treated with template-based high-dose-rate interstitial brachytherapy boost for post-operative recurrent gynecological malignancies: A retrospective analysis.
MUPIT
brachytherapy
interstitial radiotherapy boost
vaginal vault
Journal
Journal of contemporary brachytherapy
ISSN: 1689-832X
Titre abrégé: J Contemp Brachytherapy
Pays: Poland
ID NLM: 101506276
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
16
03
2022
accepted:
19
12
2022
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
ppublish
Résumé
To report the clinical outcomes in patients treated with Martinez universal perineal interstitial template (MUPIT)-based interstitial brachytherapy boost for primary and recurrent vault and vaginal cancers, and to perform a comparative analysis with our previously published series of similar patients. One hundred and seventeen patients treated between January, 2009 and December, 2015 were evaluated. Descriptive statistics for the patterns of relapse, local recurrence-free survival (LRFS), disease-free survival (DFS), overall survival (OS), and late toxicities were carried out. Kaplan-Meier curves were used for survival analysis. All variables with the potential to affect outcomes were tested using log-rank test for statistical significance. At a median follow-up of 63 months, LRFS, DFS, and OS at 3/5 years were 77.1%/74.7%, 61%/52%, and 72.3%/63.1%, respectively. Overall treatment time (OTT) of 56 days did not affect outcomes. Bulky tumors and OTT > 63 days adversely affected LRFS. Overall treatment time also significantly impacted DFS and OS. Grade 3-4 late bladder toxicities were observed in 1.7% patients, and grade 3-4 late rectal toxicities in 5% patients. Compared to our previous series, the outcome in the current series is better in terms of severe late toxicities (5% improvement in rectal toxicity, and 2.7% improvement in bladder toxicity) and OS by 10%. This could be attributed to the increasing use of concurrent chemotherapy and relative optimization strategies for organs at risk. Patients with primary and recurrent vault and vaginal cancers treated with high-dose-rate interstitial brachytherapy boost using MUPIT resulted in modest clinical outcomes and acceptable late toxicities. OTT was the most important factor affecting the outcomes.
Identifiants
pubmed: 36819468
doi: 10.5114/jcb.2022.123976
pii: 49846
pmc: PMC9924156
doi:
Types de publication
Journal Article
Langues
eng
Pagination
560-567Informations de copyright
Copyright © 2022 Termedia.
Déclaration de conflit d'intérêts
The authors report no conflict of interest.
Références
Gynecol Oncol. 1995 Feb;56(2):255-61
pubmed: 7896194
Int J Radiat Oncol Biol Phys. 2022 Sep 1;114(1):111-119
pubmed: 35654306
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):310-319
pubmed: 31682968
J Contemp Brachytherapy. 2019 Aug;11(4):293-306
pubmed: 31523229
Int J Womens Health. 2014 May 28;6:555-64
pubmed: 24920937
Lancet. 1997 Aug 23;350(9077):535-40
pubmed: 9284774
J Obstet Gynaecol India. 2013 Apr;63(2):128-34
pubmed: 24431620
Gynecol Oncol. 1984 Mar;17(3):340-8
pubmed: 6423462
Brachytherapy. 2012 Jan-Feb;11(1):68-75
pubmed: 22265440
Semin Radiat Oncol. 2020 Oct;30(4):291-299
pubmed: 32828385
Reprod Health. 2018 Jan 5;15(1):3
pubmed: 29304867
Brachytherapy. 2015 Nov-Dec;14(6):881-8
pubmed: 26409708
Int J Radiat Oncol Biol Phys. 1984 Feb;10(2):297-305
pubmed: 6706724
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e617-22
pubmed: 22300566
Brachytherapy. 2013 May-Jun;12(3):248-53
pubmed: 23453679
Brachytherapy. 2013 Mar-Apr;12(2):156-61
pubmed: 23182042
Radiother Oncol. 2016 Sep;120(3):447-454
pubmed: 27157510
Radiother Oncol. 2016 Sep;120(3):519-525
pubmed: 27528120
Brachytherapy. 2022 Nov-Dec;21(6):823-832
pubmed: 36192312
J Gynecol Oncol. 2017 May;28(3):e34
pubmed: 28382797
J Cancer Res Ther. 2007 Apr-Jun;3(2):111-5
pubmed: 17998736
Brachytherapy. 2014 Jul-Aug;13(4):337-42
pubmed: 24176863
Brachytherapy. 2017 Jan - Feb;16(1):126-132
pubmed: 27816539
Clin Oncol (R Coll Radiol). 2021 Dec;33(12):773-779
pubmed: 34092463
Brachytherapy. 2016 Jan-Feb;15(1):49-56
pubmed: 26614237
Ann Surg Oncol. 2015 Apr;22(4):1349-52
pubmed: 25297903
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593